Stock analysts at Brean Capital began coverage on shares of Neuralstem Inc. (NASDAQ:CUR) in a note issued to investors on Tuesday, StockTargetPrices.com reports. The brokerage set a “buy” rating and a $4.00 price target on the stock.
Separately, Roth Capital assumed coverage on Neuralstem in a report on Monday, August 29th. They set a “buy” rating and a $1.20 price objective on the stock.
Neuralstem (NASDAQ:CUR) opened at 0.314 on Tuesday. Neuralstem has a 52-week low of $0.19 and a 52-week high of $1.35. The stock’s market cap is $36.03 million. The firm has a 50-day moving average price of $0.29 and a 200 day moving average price of $0.39.
Neuralstem (NASDAQ:CUR) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. Neuralstem had a negative return on equity of 574.32% and a negative net margin of 173,849.97%. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.50 million. Equities analysts anticipate that Neuralstem will post ($0.17) earnings per share for the current year.
Several large investors have recently modified their holdings of CUR. Blair William & Co. IL purchased a new stake in shares of Neuralstem during the second quarter worth $122,000. Vanguard Group Inc. increased its stake in shares of Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock worth $984,000 after buying an additional 606,500 shares during the period. Finally, Sabby Management LLC purchased a new stake in shares of Neuralstem during the second quarter worth $1,893,000. Institutional investors and hedge funds own 18.20% of the company’s stock.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.